L-Ornithine Fatigue Randomized Trial Evidence Table

Structured evidence table for L-Ornithine Fatigue Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
L-Ornithine Fatigue Randomized TrialBy synthesizing data from animal models and human studies, this review seeks to determine whether LOLA intervention can ameliorate liver injury and halt fibrosis progression via both ammonia‐dependent and independent pathways, thereby providing an evidence base for its potential expanded use in the management of MASLD patients.1Ismaiel Abdulrahman (2026)Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
L-Ornithine Fatigue Randomized TrialWe specifically included studies where hepatic steatosis or fibrosis was associated with metabolic dysfunction or toxic liver injury mimicking these pathologies, and where the intervention involved the administration of LOLA or L‐aspartate.1Ismaiel Abdulrahman (2026)Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
L-Ornithine Fatigue Randomized TrialThe methodological quality and potential risk of bias of the included studies were evaluated using tools appropriate for the specific study designs.1Ismaiel Abdulrahman (2026)Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
L-Ornithine Fatigue Randomized TrialCurrent pharmacological management of MASLD is limited, with lifestyle modification and weight loss remaining the cornerstone of therapy.,While agents such as resmetirom and semaglutide are currently recommended in advanced MASH fibrosis,,there is no universally adopted pharmacotherapy that targets the pleiotropic metabolic defects of the disease, particularly the ammonia‐related toxicity.1Ismaiel Abdulrahman (2026)Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
L-Ornithine Fatigue Randomized TrialResults: While L-ornithine did not affect saliva cortisol levels, it significantly improved the fatigue-inertia and anger-hostility scales of the Profile of Mood States on the morning after the TSST in the L-ornithine group compared to the placebo group.2Moriyasu K (2024)Effects of Oral Ingestion of L-Ornithine on Mental Stress and Fatigue Based on the Trier Social Stress Test in Healthy Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.
L-Ornithine Fatigue Randomized TrialConclusions: In conclusion, L-ornithine could potentially improve interpersonal social-stress-associated fatigue without involving the HPA axis.2Moriyasu K (2024)Effects of Oral Ingestion of L-Ornithine on Mental Stress and Fatigue Based on the Trier Social Stress Test in Healthy Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.
L-Ornithine Fatigue Randomized TrialBackground: With changes in the social environment typified by COVID-19, an increasing number of people are suffering from mental stress in interpersonal relationships and the resulting fatigue in recent years.2Moriyasu K (2024)Effects of Oral Ingestion of L-Ornithine on Mental Stress and Fatigue Based on the Trier Social Stress Test in Healthy Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.
L-Ornithine Fatigue Randomized TrialL-ornithine oral ingestion reportedly suppresses the secretion of cortisol, a stress marker, through the hypothalamic-pituitary-adrenal (HPA) axis.2Moriyasu K (2024)Effects of Oral Ingestion of L-Ornithine on Mental Stress and Fatigue Based on the Trier Social Stress Test in Healthy Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.
topicL-Ornithine Fatigue Randomized Trial
claimBy synthesizing data from animal models and human studies, this review seeks to determine whether LOLA intervention can ameliorate liver injury and halt fibrosis progression via both ammonia‐dependent and independent pathways, thereby providing an evidence base for its potential expanded use in the management of MASLD patients.
evidence level1
citationIsmaiel Abdulrahman (2026)
sourceCan ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
topicL-Ornithine Fatigue Randomized Trial
claimWe specifically included studies where hepatic steatosis or fibrosis was associated with metabolic dysfunction or toxic liver injury mimicking these pathologies, and where the intervention involved the administration of LOLA or L‐aspartate.
evidence level1
citationIsmaiel Abdulrahman (2026)
sourceCan ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
topicL-Ornithine Fatigue Randomized Trial
claimThe methodological quality and potential risk of bias of the included studies were evaluated using tools appropriate for the specific study designs.
evidence level1
citationIsmaiel Abdulrahman (2026)
sourceCan ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
topicL-Ornithine Fatigue Randomized Trial
claimCurrent pharmacological management of MASLD is limited, with lifestyle modification and weight loss remaining the cornerstone of therapy.,While agents such as resmetirom and semaglutide are currently recommended in advanced MASH fibrosis,,there is no universally adopted pharmacotherapy that targets the pleiotropic metabolic defects of the disease, particularly the ammonia‐related toxicity.
evidence level1
citationIsmaiel Abdulrahman (2026)
sourceCan ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
topicL-Ornithine Fatigue Randomized Trial
claimResults: While L-ornithine did not affect saliva cortisol levels, it significantly improved the fatigue-inertia and anger-hostility scales of the Profile of Mood States on the morning after the TSST in the L-ornithine group compared to the placebo group.
evidence level2
citationMoriyasu K (2024)
sourceEffects of Oral Ingestion of L-Ornithine on Mental Stress and Fatigue Based on the Trier Social Stress Test in Healthy Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.
topicL-Ornithine Fatigue Randomized Trial
claimConclusions: In conclusion, L-ornithine could potentially improve interpersonal social-stress-associated fatigue without involving the HPA axis.
evidence level2
citationMoriyasu K (2024)
sourceEffects of Oral Ingestion of L-Ornithine on Mental Stress and Fatigue Based on the Trier Social Stress Test in Healthy Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.
topicL-Ornithine Fatigue Randomized Trial
claimBackground: With changes in the social environment typified by COVID-19, an increasing number of people are suffering from mental stress in interpersonal relationships and the resulting fatigue in recent years.
evidence level2
citationMoriyasu K (2024)
sourceEffects of Oral Ingestion of L-Ornithine on Mental Stress and Fatigue Based on the Trier Social Stress Test in Healthy Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.
topicL-Ornithine Fatigue Randomized Trial
claimL-ornithine oral ingestion reportedly suppresses the secretion of cortisol, a stress marker, through the hypothalamic-pituitary-adrenal (HPA) axis.
evidence level2
citationMoriyasu K (2024)
sourceEffects of Oral Ingestion of L-Ornithine on Mental Stress and Fatigue Based on the Trier Social Stress Test in Healthy Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.

Source documents

  1. Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
  2. Effects of Oral Ingestion of L-Ornithine on Mental Stress and Fatigue Based on the Trier Social Stress Test in Healthy Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.